Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 28, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 3,266,000 ordinary shares of 25 pence each.
- Purchase Price: 1,295.0352 pence per share.
- Treasury Holdings: 415,539,158 shares (representing 7.40% of total voting rights).
- Shares in Issue: 5,608,585,518 shares (excluding Treasury shares).
Material Changes
The material change reported is the increase in the company's Treasury share holdings following the purchase on September 28, 2007. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,608,585,518) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share percentage (7.40%) for voting rights calculations.
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.